Cardiff Oncology Inc. (CRDF)
| Bid | 3.31 |
| Market Cap | 220.53M |
| Revenue (ttm) | 954.93K |
| Net Income (ttm) | -63.43M |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -3.49 |
| Forward PE | -3.36 |
| Analyst | Buy |
| Ask | 3.32 |
| Volume | 239,302 |
| Avg. Volume (20D) | 1,103,353 |
| Open | 3.47 |
| Previous Close | 3.44 |
| Day's Range | 3.29 - 3.46 |
| 52-Week Range | 2.01 - 6.38 |
| Beta | 1.73 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevac...
Analyst Forecast
According to 3 analyst ratings, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 201.66% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With OnvansertibCardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II resu...